CJC-1295 DAC + Ipamorelin (5 mg + 5 mg Vial) Dosage Protocol
This blend pairs CJC-1295 with Drug Affinity Complex (DAC) — a long-acting GHRH analog with ~6–8 day half-life — with Ipamorelin, the most selective GHS-R agonist. Unlike CJC-No DAC blends, the DAC version enables true once-weekly dosing for the GHRH component while Ipamorelin is dosed daily for pulsatile GH stimulation.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for stacked GH secretagogue protocol
CJC-1295 DAC (5 mg Vial) — Subcutaneous, Once Weekly
Reconstitution: 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) → 25 mcg per unit
| Phase | Weekly Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Standard | 1000 mcg (1.0 mg) | 40 units (0.40 mL) | Once weekly |
| Aggressive | 2000 mcg (2.0 mg) | 80 units (0.80 mL) | Once weekly |
Note: At 2.5 mg/mL, each 5 mg vial provides 2.5 standard doses (1 mg each) or 1.25 aggressive doses (2 mg each).
CJC-1295 DAC Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto powder.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F).
Ipamorelin (5 mg Vial) — Subcutaneous, Once Daily
Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL (1666.7 mcg/mL) → 16.67 mcg per unit
| Phase | Daily Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Weeks 1–2 (Initiation) | 100 mcg (0.1 mg) | 6 units (0.06 mL) | Once daily |
| Weeks 3–4 (Titration) | 150 mcg (0.15 mg) | 9 units (0.09 mL) | Once daily |
| Weeks 5+ (Maintenance) | 200 mcg (0.2 mg) | 12 units (0.12 mL) | Once daily |
| Aggressive (Optional) | 300 mcg (0.3 mg) | 18 units (0.18 mL) | Once daily or split 2×/day |
For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Ipamorelin Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F).
Combined Stack Schedule — Standard Approach
| Week | CJC-1295 DAC (Weekly) | Ipamorelin (Daily) |
|---|---|---|
| Weeks 1–2 | 1000 mcg (40 units) once weekly | 100 mcg (6 units) once daily |
| Weeks 3–4 | 1000 mcg (40 units) once weekly | 150 mcg (9 units) once daily |
| Weeks 5–12 | 1000 mcg (40 units) once weekly | 200 mcg (12 units) once daily |
Timing: CJC-1295 DAC is typically administered on a fixed day each week. Ipamorelin is commonly administered before bed to coincide with natural nocturnal GH pulses.
Important: This guide is for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Supplies Needed
Plan based on an 8–16 week stacked protocol with standard dosing (CJC-1295 DAC 1 mg/week + Ipamorelin 200 mcg/day at maintenance).
| Item | Quantity |
|---|---|
| CJC-1295 DAC Vials (5 mg each) | 8 weeks (8 mg total) → 2 vials 12 weeks (12 mg total) → 3 vials 16 weeks (16 mg total) → 4 vials |
| Ipamorelin Vials (5 mg each) | 8 weeks (56 days at ~200 mcg/day) → 3 vials 12 weeks (84 days) → 4 vials 16 weeks (112 days) → 5 vials |
| Insulin Syringes (U-100) | Per week: 1 (CJC) + 7 (Ipamorelin) = 8 syringes 8 weeks: 64 syringes 12 weeks: 96 syringes 16 weeks: 128 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks: CJC (2 × 2 mL = 4 mL) + Ipam (3 × 3 mL = 9 mL) = 13 mL → 2 × 10 mL bottles 12 weeks: CJC (3 × 2 mL = 6 mL) + Ipam (4 × 3 mL = 12 mL) = 18 mL → 2 × 10 mL bottles 16 weeks: CJC (4 × 2 mL = 8 mL) + Ipam (5 × 3 mL = 15 mL) = 23 mL → 3 × 10 mL bottles |
| Alcohol Swabs | Per week: ~16 swabs (2/day for Ipamorelin + 2 for CJC weekly) 8 weeks: 128 swabs → 2 × 100-count boxes 12 weeks: 192 swabs → 2 × 100-count boxes 16 weeks: 256 swabs → 3 × 100-count boxes |
How This Works
CJC-1295 with DAC (Drug Affinity Complex) uses a maleimido-propionic acid (MPA) modification that reacts covalently with lysine-rich albumin in the bloodstream, dramatically extending half-life from ~30 minutes (no-DAC version) to approximately 6–8 days. This means a single weekly injection maintains elevated GHRH signaling throughout the week, providing a steady 'tidal' GHRH background rather than a pulse.
Ipamorelin, dosed daily, provides the ghrelin receptor (GHS-R1a) stimulation component — producing discrete GH pulses with the highest receptor selectivity of any GHRP (no cortisol, prolactin, or ACTH elevation at therapeutic doses). The combination of sustained GHRH background (CJC-DAC weekly) plus daily ghrelin receptor pulses (Ipamorelin) provides complementary synergistic GH stimulation.
Potential Benefits & Side Effects
Potential Benefits
- CJC-1295 DAC: once-weekly convenience — no daily GHRH injections required.
- Ipamorelin: cleanest GHRP — GH stimulation without cortisol/ACTH/prolactin elevation.
- Synergistic: GHRH amplifies GH pulse amplitude; GHRP increases GH pulse frequency.
- Sustained GHRH background may support IGF-1 elevation across the week.
- Well-tolerated — ipamorelin's selectivity minimizes side effects.
- Long track record in research community.
Side Effect Profile
- Mild fluid retention during first 2–4 weeks (GH-mediated).
- Possible mild morning grogginess (GH activity during sleep).
- Injection-site reactions.
- CJC-DAC: some report decreased GH pulsatility with continuous use vs cycling.
- WADA prohibited — all GH secretagogues.
- Avoid if active malignancy or diabetic retinopathy.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | −20°C, up to 24 months |
| Reconstituted | 2–8°C | Up to 14 days |